Filing Details

Accession Number:
0001209191-22-060077
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-12-06 17:31:47
Reporting Period:
2022-12-02
Accepted Time:
2022-12-06 17:31:47
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1287098 Maxcyte Inc. MXCT Services-Commercial Physical & Biological Research (8731) 522210438
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1874572 M. Thomas Ross C/O Maxcyte, Inc.
9713 Key West Avenue, Suite 400
Rockville MD 20850
Evp, Global Sales & Marketing No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-12-02 15,000 $1.08 15,000 No 4 M Direct
Common Stock Disposition 2022-12-02 15,000 $6.02 0 No 4 S Direct
Common Stock Acquisiton 2022-12-05 14,133 $1.08 14,133 No 4 M Direct
Common Stock Disposition 2022-12-05 14,133 $5.59 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2022-12-02 15,000 $0.00 15,000 $1.08
Common Stock Employee Stock Option (right to buy) Disposition 2022-12-05 14,133 $0.00 14,133 $1.08
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
45,734 2026-06-13 No 4 M Direct
31,601 2026-06-13 No 4 M Direct
Footnotes
  1. The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022.
  2. This exercise price is in U.S. Dollars and reflects the conversion of British pounds, the currency in which the exercise price was expressed at the time of grant.
  3. The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.00 to $6.05, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
  4. The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.35 to $5.98, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
  5. This option is fully vested and exercisable.